Mutated COVID-19 may foretell a great risk for mankind in the future

Dawood, Ali Adel

doi:10.1016/j.nmni.2020.100673

Cited by 146 publications

(126 citation statements)

References 16 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…This could be attributed to the mutation of the N protein sequence in the coronavirus family. Dawood (2020), reported a moderate mutation of the N-protein of coronaviruses [32]. This is indicative that the SARS-COV-2 virus may have originated from mutations within the family as has been previously suggested [33].…”

Section: Codon Optimization and In Silico Cloningsupporting

confidence: 52%

Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

Chukwudozie

Chukwuanukwu

Onyekachi

et al. 2020

Preprint

View full text Add to dashboard Cite

ABSTRACTThe novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we, therefore, designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of nucleocapsid protein that aid in viral replication. Promising antigenic B-cells and T cell epitopes were predicted using computational pipelines. The peptides “RIRGGDGKMKDL” and “AFGRRGPEQTQGNFG” were the B cell linear epitopes with good antigenic index and non-allergenic property. Two CD8+ and Three CD4+ T-cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and II alleles. With these selected epitopes, a non-allergenic chimeric peptide vaccine incapable of inducing a Type II hypersensitivity reaction was constructed. The molecular interaction between the toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally, in silico cloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation.

show abstract

Section: Codon Optimization and In Silico Cloningsupporting

confidence: 52%

Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

Chukwudozie

Chukwuanukwu

Onyekachi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, recent research has indicated such factors can affect mortality rates associated with COVID-19 (e.g., (5,19). It may be necessarily to account for such factors as more data becomes available.…”

Section: Seir Compartmental Modelmentioning

confidence: 99%

Mathematical model of COVID-19 intervention scenarios for São Paulo-Brazil

Neto

Osmar²

2020

Preprint

View full text Add to dashboard Cite

The objective of the current investigation was to produce a generalized computational model to predict consequences of various reopening scenarios on COVID-19 infections rates and available hospital resources in São Paulo -Brazil. We were able to use the Susceptible-Exposed-Infected-Recovered (SEIR) model to fit both accumulated death data and corrected accumulated cases data associated with COVID-19 for both Brazil and the state of São Paulo.In addition, we were able to simulate the consequences of reopening under different possible scenarios in Brazil, in special for the state of São Paulo. The model was able to provide a predicted scenario in which reopening could occur with minimal impact on human life considering people careful behavior in combination with continued social distancing measures.

show abstract

“…An unimaginably high degree of transmission raised a question of whether evolution was stimulated by mutations. Genetic mutation analysis is essential for understanding evolution [32]. A study was conducted to understand and evaluate the genetic mutations pattern, in which eighty-six genomes of SARS-CoV-2 were selected.…”

Section: Evolution Of Covid-19mentioning

confidence: 99%

Understanding COVID-19: From Origin to Potential Therapeutics

Moazzam

Sajid

Shahid

et al. 2020

IJERPH

View full text Add to dashboard Cite

Currently, a global pandemic era of public health concerns is going on with the Coronavirus Disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported from Wuhan’s Huanan seafood market in China late December 2019. Bats, pangolins, and snakes have been nominated as salient carriers of the virus. Thanks to its high pathogenicity, it can cause severe respiratory infections. Fever, dry cough, sore throat, pneumonia, septic shock, and ground-glass opacities are the foremost clinical manifestations of COVID-19. Immunocompromised patients are at high risk for COVID-19 infection and may lead to death. Scientist and government agencies around the globe are putting forward their best efforts and resources for the effective treatment of human coronavirus infections; however, neither vaccines nor antiviral drugs are available for the treatment of human coronaviruses (HCoV) infections such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19. Since the outbreak, a plethora of research and review articles have been published. Moreover, the mass media has bombarded the public with conflicting opinions about the pandemic. There is a dire need for accurate and reliable information concerning this pandemic. In this review, we have compiled the up to date information about the origins, evolution, epidemiology, and pathogenesis of this disease. Moreover, very few reports have addressed the clinical features and current status of treatment for COVID-19; we have adequately addressed these topics in detail in this review. Finally, a detailed account of clinical trials of vaccines and other therapeutics currently in progress has been delineated.

show abstract

Mutated COVID-19 may foretell a great risk for mankind in the future

Cited by 146 publications

References 16 publications

Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In silico analysis

Mathematical model of COVID-19 intervention scenarios for São Paulo-Brazil

Understanding COVID-19: From Origin to Potential Therapeutics

Contact Info

Product

Resources

About